These blog posts explore GP2’s work in further understanding the genetic architecture of Parkinson’s disease.
Christine Klein leads the GP2 Monogenic Hub. In this post Christine shares how her interest in Parkinson’s disease genetics was sparked, which genes have been discovered so far, and the questions which are still to be answered.
In GP2, underlying data, analytical processes, and results will be made available to the research community as quickly as possible, with minimal barriers to access and use. The latest blog post by Bradford Casey highlights the value and importance of open science.
ASAP Scientific Director, Randy Schekman, expresses his personal and professional connection with Parkinson's disease in a letter to the patient community, shared by patient advocate Benjamin Stecher.